New Research Details Published by Merck Scientists About the Early Development of Verubecestat

Merck Igea Luca Dezzani

November 2, 2016

Merck has announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat. It is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is used for treating Alzheimer’s disease (AD). The latest edition of the online peer-reviewed journal Science Translational Medicine published the research first. It included results from the Phase 1 clinical trials in healthy volunteers and people with AD. The safety and efficacy of verubecestat is currently being evaluated in two pivotal Phase 3 clinical trials, EPOCH and APECS, for treating mild-to-moderate AD and prodromal AD, respectively.

Dr. Michael Egan, vice president, clinical development neurosciences, Merck Research Laboratories, said: “The development of a potential disease modifying therapy for treatment of Alzheimer’s disease has long been a focus of biomedical research. We believe this research has the potential to contribute important evidence regarding the amyloid hypothesis, a leading scientific theory for what causes Alzheimer’s disease, and we look forward to seeing the data from our ongoing Phase 3 clinical trials.”

New Research Details Published by Merck Scientists About the Early Development of Verubecestat last edit: 2016-11-10T16:22:56+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar